Abolghasemi Jamileh, Eshraghian Mohammad Reza, Nasiri Toosi Mohsen, Mahmoodi Mahmood, Rahimi Foroushani Abbas
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.
Hepat Mon. 2013 Aug 30;13(8):e10479. doi: 10.5812/hepatmon.10479. eCollection 2013.
Liver transplantation (LT) is the only treatment option for patients with advanced liver disease. Currently, liver donation to these patients, considering priorities, is based on the Model for End-Stage Liver Disease (MELD). MELD score is a tool for predicting the risk of mortality in patients with advanced liver disease. However, few studies have so far been conducted in Iran on the efficacy of MELD score of these patients.
This study reviews the present status of the MELD score and introduces a new model for optimal prediction of the risk of mortality in Iranian patients with advanced liver disease.
Data required were collected from 305 patients with advanced liver disease who enrolled in a waiting list (WL) in Imam Khomeini Hospital from May 2008 to May 2009. All of the patients were followed up for at least 3 years until they died or underwent LT. Cox regression analysis was applied to select the factors affecting their mortality. Survival curves were plotted. Wilcoxson test and receiver operating characteristics curves for survival predictive model were used to compare the scores. All calculations were performed with the SPSS (version 13.0) and R softwares.
During the study, 71 (23.3%) patients died due to liver cirrhosis and 43 (14.1%) underwent LT. Viral Hepatitis (43.7%) is the most common cause of end-stage liver disease among Iranian patients. A new model (NMELD) was proposed with the use of the natural logarithms of two blood serum variables (total bilirubin and albumin) and the patients' age (year) by applying the Cox model: NMELD = 10 × (0.736 × ln (bilirubin) - 1.312 × ln (albumin) + 0.025 × age + 1.776).
The results of the Wilcoxon test showed that there is a significant difference between the usual MELD and our proposed NMELD scores (P < 0.001). Receiver operating characteristics curve for survival predictive model indicated that the NMELD score is more efficient compared with the MELD score in predicting the risk of mortality. Since serum creatinine was not significant in NMELD score, further studies to clarify this issue are suggested.
肝移植(LT)是晚期肝病患者唯一的治疗选择。目前,考虑到优先顺序,向这些患者的肝脏捐赠是基于终末期肝病模型(MELD)。MELD评分是预测晚期肝病患者死亡风险的一种工具。然而,迄今为止在伊朗针对这些患者的MELD评分效果进行的研究很少。
本研究回顾了MELD评分的现状,并引入一种新模型以优化预测伊朗晚期肝病患者的死亡风险。
所需数据收集自2008年5月至2009年5月在伊玛目霍梅尼医院登记在等待名单(WL)中的305例晚期肝病患者。所有患者均随访至少3年,直至死亡或接受肝移植。应用Cox回归分析来选择影响其死亡率的因素。绘制生存曲线。使用生存预测模型的Wilcoxson检验和受试者工作特征曲线来比较评分。所有计算均使用SPSS(13.0版)和R软件进行。
在研究期间,71例(23.3%)患者死于肝硬化,43例(14.1%)接受了肝移植。病毒性肝炎(43.7%)是伊朗患者终末期肝病最常见的病因。通过应用Cox模型,利用两个血清变量(总胆红素和白蛋白)的自然对数以及患者年龄(岁),提出了一种新模型(NMELD):NMELD = 10 × (0.736 × ln(胆红素) - 1.312 × ln(白蛋白) + 0.025 × 年龄 + 1.776)。
Wilcoxson检验结果表明,常规MELD评分与我们提出的NMELD评分之间存在显著差异(P < 0.001)。生存预测模型的受试者工作特征曲线表明,在预测死亡风险方面,NMELD评分比MELD评分更有效。由于血清肌酐在NMELD评分中不显著,建议进一步研究以阐明这一问题。